Research Project

Project Title:	A randomized, multicenter, double-blind, parallel, active-control study of the effects of Sparsentan, a dual endothelin receptor and angiotensin receptor blocker, on renal outcomes in patients with primary focal segmental glomerulosclerosis
Project Type:	Clinical Trial, Enrolment ongoing
Disease group(s):	Immune glomerulopathies
Project Summary:	A randomized, multicenter, double-blind, parallel, active-control study of the effects of Sparsentan, a dual endothelin receptor and angiotensin receptor blocker, on renal outcomes in patients with primary focal segmental glomerulosclerosis
Lead principal investigator(s):	Olga Baraldi, Bologna
Co-investigator(s):	Valeria Aiello, Bologna Simona Barbuto, Bologna
Project Period:	04/2020 - 12/2024
Sponsors:	Industry